Fermer le menu


Osivax Enters Research Collaboration with the NIAID for the Evaluation of Combination Approach to Broad-Spectrum Influenza Vaccines

Lyon, France – May 17, 2022

Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, today announced that it has entered a research collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to conduct a preclinical evaluation combining Osivax’ T-cell based influenza candidate, OVX836, with a range of the NIAID Vaccine Research Center (VRC)’s influenza vaccine candidates. The immune responses produced by OVX836 involve T-cells against the nucleoprotein (NP), a highly conserved internal antigen across flu strains, and those produced by the NIAID VRC vaccine candidates involve B-cells against hemagglutinin (HA) surface antigens. As both approaches are directed to potential pandemic influenza strains, Osivax and NIAID will evaluate potential synergies between these respective immune responses and potential additive effects in animal challenge models in an effort to create improved, broad-spectrum influenza vaccines.



Plus d'infos